HUE041397T2 - Arilkinazolinok - Google Patents

Arilkinazolinok

Info

Publication number
HUE041397T2
HUE041397T2 HUE14726074A HUE14726074A HUE041397T2 HU E041397 T2 HUE041397 T2 HU E041397T2 HU E14726074 A HUE14726074 A HU E14726074A HU E14726074 A HUE14726074 A HU E14726074A HU E041397 T2 HUE041397 T2 HU E041397T2
Authority
HU
Hungary
Prior art keywords
arylquinazolines
Prior art date
Application number
HUE14726074A
Other languages
English (en)
Inventor
Thomas Fuchss
Ulrich Emde
Hans-Peter Buchstaller
Werner Mederski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE041397(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUE041397T2 publication Critical patent/HUE041397T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Closures For Containers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE14726074A 2013-05-11 2014-05-08 Arilkinazolinok HUE041397T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102013008118.1A DE102013008118A1 (de) 2013-05-11 2013-05-11 Arylchinazoline

Publications (1)

Publication Number Publication Date
HUE041397T2 true HUE041397T2 (hu) 2019-05-28

Family

ID=50729442

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14726074A HUE041397T2 (hu) 2013-05-11 2014-05-08 Arilkinazolinok

Country Status (32)

Country Link
US (5) US9732094B2 (hu)
EP (1) EP2994467B1 (hu)
JP (1) JP6562903B2 (hu)
KR (1) KR102292811B1 (hu)
CN (1) CN105358552B (hu)
AR (2) AR096235A1 (hu)
AU (1) AU2014267723B2 (hu)
BR (1) BR112015027951B1 (hu)
CA (1) CA2911668C (hu)
CL (1) CL2015003285A1 (hu)
DE (1) DE102013008118A1 (hu)
DK (1) DK2994467T3 (hu)
ES (1) ES2693774T3 (hu)
HK (1) HK1221719A1 (hu)
HR (1) HRP20181775T1 (hu)
HU (1) HUE041397T2 (hu)
IL (2) IL242348B (hu)
LT (1) LT2994467T (hu)
MX (1) MX362183B (hu)
MY (1) MY173126A (hu)
NZ (1) NZ713362A (hu)
PE (1) PE20152001A1 (hu)
PH (1) PH12015502339A1 (hu)
PL (1) PL2994467T3 (hu)
PT (1) PT2994467T (hu)
RS (1) RS57838B1 (hu)
RU (1) RU2701193C2 (hu)
SG (1) SG11201509268YA (hu)
SI (1) SI2994467T1 (hu)
TR (1) TR201816069T4 (hu)
UA (1) UA116020C2 (hu)
WO (1) WO2014183850A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JP6885869B2 (ja) 2015-02-26 2021-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
WO2017166104A1 (en) * 2016-03-30 2017-10-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
WO2018114776A1 (en) 2016-12-19 2018-06-28 Merck Patent Gmbh Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
JP7295025B2 (ja) * 2017-03-30 2023-06-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態
US11053233B2 (en) 2017-03-30 2021-07-06 Merck Patent Gmbh Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
KR102644408B1 (ko) * 2017-03-30 2024-03-07 메르크 파텐트 게엠베하 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
BR112019020269A2 (pt) 2017-03-30 2020-04-22 Merck Patent Gmbh formulação farmacêutica
EP3740480B1 (en) 2018-01-17 2024-03-06 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CN112512576A (zh) * 2018-05-04 2021-03-16 默克专利有限公司 PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
WO2020068600A1 (en) * 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
US20220154220A1 (en) 2018-12-21 2022-05-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Small molecules for increasing precise genome editing efficiency
CN111909144A (zh) * 2019-05-10 2020-11-10 山东轩竹医药科技有限公司 喹唑啉类dna-pk抑制剂
KR20220027183A (ko) * 2019-06-27 2022-03-07 메드샤인 디스커버리 아이엔씨. Dna-pk 억제제로서의 퀴놀린 및 시놀린 유도체
CN112300132A (zh) * 2019-07-30 2021-02-02 山东轩竹医药科技有限公司 芳基喹唑啉类dna-pk抑制剂
WO2022058323A1 (en) 2020-09-18 2022-03-24 Merck Patent Gmbh Compounds for the treatment of viral infections
AU2021365816A1 (en) * 2020-10-19 2023-06-22 Baruch S. Blumberg Institute Methods and kits for diagnosing and treating cancers
WO2022135555A1 (zh) * 2020-12-24 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN116670128A (zh) * 2020-12-28 2023-08-29 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法
AU2022258733A1 (en) 2021-04-17 2023-11-30 Intellia Therapeutics, Inc. Inhibitors of dna-dependent protein kinase and compositions and uses thereof
CN115557900B (zh) * 2022-11-11 2024-03-15 常州大学 一种3-取代哒嗪衍生物的合成方法
WO2024104815A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
WO2024104818A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK400992A3 (en) 1990-11-06 1995-08-09 Pfizer Quinazolines derivatives for enhancing antitumor activity
CN1169527A (zh) * 1996-06-24 1998-01-07 考克库姆·索尼克斯公司 低频声的声发射器
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY
US7276519B2 (en) 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2013206A1 (en) * 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
EP2046799B1 (en) * 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
SI2057156T1 (sl) * 2006-08-23 2017-06-30 Kudos Pharmaceuticals Limited Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
TW200829594A (en) * 2006-12-07 2008-07-16 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
GEP20125603B (en) * 2007-10-29 2012-08-10 Nacto Pharma Ltd Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2408766A1 (en) 2009-03-18 2012-01-25 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
WO2010106436A2 (en) * 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
CN102803227B (zh) 2010-03-16 2016-01-20 默克专利有限公司 吗啉基喹唑啉
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2013001612A (es) 2010-08-10 2013-07-05 Abbvie Inc Moduladores de trpv3 novedosos.
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
DE102011118830A1 (de) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CN104981247A (zh) 2012-09-06 2015-10-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2015011284A2 (en) 2013-07-25 2015-01-29 Fondazione Telethon Inhibitors of fapp2 and uses thereof
WO2018114776A1 (en) * 2016-12-19 2018-06-28 Merck Patent Gmbh Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
US11053233B2 (en) * 2017-03-30 2021-07-06 Merck Patent Gmbh Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
JP7295025B2 (ja) * 2017-03-30 2023-06-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態
BR112019020269A2 (pt) * 2017-03-30 2020-04-22 Merck Patent Gmbh formulação farmacêutica

Also Published As

Publication number Publication date
RU2015153094A (ru) 2017-06-16
US20220117970A1 (en) 2022-04-21
KR102292811B1 (ko) 2021-08-23
US11065253B2 (en) 2021-07-20
ES2693774T3 (es) 2018-12-13
AU2014267723A1 (en) 2015-12-24
US9732094B2 (en) 2017-08-15
US20190142833A1 (en) 2019-05-16
US10383874B2 (en) 2019-08-20
RS57838B1 (sr) 2018-12-31
IL242348B (en) 2022-01-01
PH12015502339B1 (en) 2016-02-22
BR112015027951A2 (pt) 2017-07-25
CA2911668A1 (en) 2014-11-20
BR112015027951A8 (pt) 2019-12-24
DE102013008118A1 (de) 2014-11-13
MX362183B (es) 2019-01-08
IL285390A (en) 2021-09-30
SI2994467T1 (sl) 2018-12-31
US20200069690A1 (en) 2020-03-05
PE20152001A1 (es) 2016-01-13
TR201816069T4 (tr) 2018-11-21
CN105358552A (zh) 2016-02-24
KR20160006231A (ko) 2016-01-18
RU2015153094A3 (hu) 2018-03-26
UA116020C2 (uk) 2018-01-25
US20170290836A1 (en) 2017-10-12
EP2994467A1 (de) 2016-03-16
MY173126A (en) 2019-12-30
CA2911668C (en) 2021-07-06
AU2014267723B2 (en) 2018-05-31
CL2015003285A1 (es) 2016-05-27
PH12015502339A1 (en) 2016-02-22
PT2994467T (pt) 2018-11-16
US10172859B2 (en) 2019-01-08
SG11201509268YA (en) 2015-12-30
CN105358552B (zh) 2018-04-27
RU2701193C2 (ru) 2019-09-25
BR112015027951B1 (pt) 2022-05-31
NZ713362A (en) 2020-09-25
MX2015015512A (es) 2016-02-05
AR124607A2 (es) 2023-04-12
DK2994467T3 (en) 2018-10-29
AR096235A1 (es) 2015-12-16
WO2014183850A1 (de) 2014-11-20
JP2016522190A (ja) 2016-07-28
US20160083401A1 (en) 2016-03-24
EP2994467B1 (de) 2018-08-01
HK1221719A1 (zh) 2017-06-09
PL2994467T3 (pl) 2019-03-29
LT2994467T (lt) 2018-11-12
HRP20181775T1 (hr) 2018-12-28
JP6562903B2 (ja) 2019-08-21

Similar Documents

Publication Publication Date Title
HRP20181775T1 (hr) Arilkinazolini
DK3736291T3 (en) Anti-FCRH5-antistoffer
EP3000028A4 (en) AUTOMATIC ADDING TO AN AGENDA
EP2957205A4 (en) HAND DRYER
GB201304236D0 (en) Hand-warmer
EP2970310A4 (en) 5-Bromo-indirubins
AU353643S (en) Stamphousing
EP2853297A4 (en) kendama
DK3056208T3 (en) Immunpotentiator
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
GB201301617D0 (en) T-Monitor
EP3014557A4 (en) TELEPHONE ON FILE
GB201300001D0 (en) Envirep - environment replicater
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
AU353329S (en) Kettlebell
AU353331S (en) Kettlebell
AU353327S (en) Kettlebell
AU353328S (en) Kettlebell
AU353326S (en) Kettlebell
AU353325S (en) Kettlebell
AU353330S (en) Kettlebell
AP00812S1 (en) Stumbelbloc
AU2013231V (en) Bonsca7200 Scaevola aemula